Krooninen sepelvaltimo-oireyhtymä, näytönastekatsausten kirjallisuusviitteet

Kirjallisuutta

1. Ambrosetti M, Abreu A, Corrà U ym. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2020;: «PMID: 33611446»PubMed
2. Andersson C, Shilane D, Go AS ym. ß-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol 2014;64:247-52 «PMID: 25034059»PubMed
3. Bangalore S, Steg G, Deedwania P ym. ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340-9 «PMID: 23032550»PubMed
4. Bao B, Ozasa N, Morimoto T ym. ß-Blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction. Cardiovasc Interv Ther 2013;28:139-47 «PMID: 23054967»PubMed
5. Budoff MJ, Dowe D, Jollis JG ym. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. J Am Coll Cardiol 2008;52:1724-32 «PMID: 19007693»PubMed
6. Cannon CP, Pratley R, Dagogo-Jack S ym. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020;383:1425-1435 «PMID: 32966714»PubMed
7. Chaitman BR, Alexander KP, Cyr DD ym. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. Circulation 2021;143:790-804 «PMID: 33267610»PubMed
8. D'Andrea E, Kesselheim AS, Franklin JM ym. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol 2020;19:154 «PMID: 32993654»PubMed
9. Dangas GD, Farkouh ME, Sleeper LA ym. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial. J Am Coll Cardiol 2014;64:1189-97 «PMID: 25236509»PubMed
10. Dibben G, Faulkner J, Oldridge N ym. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2021;11:CD001800 «PMID: 34741536»PubMed
11. Douglas PS, Hoffmann U, Patel MR ym. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med 2015;372:1291-300 «PMID: 25773919»PubMed
12. Farkouh ME, Domanski M, Dangas GD ym. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol 2019;73:629-638 «PMID: 30428398»PubMed
13. Farkouh ME, Domanski M, Sleeper LA ym. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012;367:2375-84 «PMID: 23121323»PubMed
14. Fearon WF, Zimmermann FM, De Bruyne B ym. Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. N Engl J Med 2022;386:128-137 «PMID: 34735046»PubMed
15. Freemantle N, Cleland J, Young P ym. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7 «PMID: 10381708»PubMed
16. Gerstein HC, Colhoun HM, Dagenais GR ym. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-130 «PMID: 31189511»PubMed
17. Gonçalves C, Raimundo A, Abreu A ym. Exercise Intensity in Patients with Cardiovascular Diseases: Systematic Review with Meta-Analysis. Int J Environ Res Public Health 2021;18: «PMID: 33808248»PubMed
18. Hernandez AF, Green JB, Janmohamed S ym. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:1519-1529 «PMID: 30291013»PubMed
19. Holman RR, Bethel MA, Mentz RJ ym. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017;377:1228-1239 «PMID: 28910237»PubMed
20. Husain M, Birkenfeld AL, Donsmark M ym. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019;381:841-851 «PMID: 31185157»PubMed
21. Knuuti J, Ballo H, Juarez-Orozco LE ym. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J 2018;39:3322-3330 «PMID: 29850808»PubMed
22. Knuuti J, Wijns W, Saraste A ym. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-477 «PMID: 31504439»PubMed
23. Kristensen SL, Rørth R, Jhund PS ym. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776-785 «PMID: 31422062»PubMed
24. Laukkanen JA, Kunutsor SK. Revascularization versus medical therapy for the treatment of stable coronary artery disease: A meta-analysis of contemporary randomized controlled trials. Int J Cardiol 2021;324:13-21 «PMID: 33068645»PubMed
25. Lowenstern A, Alexander KP, Hill CL ym. Age-Related Differences in the Noninvasive Evaluation for Possible Coronary Artery Disease: Insights From the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Trial. JAMA Cardiol 2020;5:193-201 «PMID: 31738382»PubMed
26. Maron DJ, Hochman JS, Reynolds HR ym. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med 2020;382:1395-1407 «PMID: 32227755»PubMed
27. Marso SP, Bain SC, Consoli A ym. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-1844 «PMID: 27633186»PubMed
28. Marso SP, Daniels GH, Brown-Frandsen K ym. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311-22 «PMID: 27295427»PubMed
29. McGuire DK, Shih WJ, Cosentino F ym. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol 2021;6:148-158 «PMID: 33031522»PubMed
30. Meijboom WB, Meijs MF, Schuijf JD ym. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol 2008;52:2135-44 «PMID: 19095130»PubMed
31. Menke J, Unterberg-Buchwald C, Staab W ym. Head-to-head comparison of prospectively triggered vs retrospectively gated coronary computed tomography angiography: Meta-analysis of diagnostic accuracy, image quality, and radiation dose. Am Heart J 2013;165:154-63.e3 «PMID: 23351817»PubMed
32. Navarese EP, Lansky AJ, Kereiakes DJ ym. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. Eur Heart J 2021;42:4638-4651 «PMID: 34002203»PubMed
33. Neal B, Perkovic V, Mahaffey KW ym. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-657 «PMID: 28605608»PubMed
34. Ozasa N, Kimura T, Morimoto T ym. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol 2010;106:1225-33 «PMID: 21029817»PubMed
35. Paech DC, Weston AR. A systematic review of the clinical effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of suspected coronary artery disease. BMC Cardiovasc Disord 2011;11:32 «PMID: 21679468»PubMed
36. Perkovic V, Jardine MJ, Neal B ym. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019;380:2295-2306 «PMID: 30990260»PubMed
37. Pfeffer MA, Claggett B, Diaz R ym. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015;373:2247-57 «PMID: 26630143»PubMed
38. Romero-Díaz J, Vargas-Vóracková F, Kimura-Hayama E ym. Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology (Oxford) 2012;51:110-9 «PMID: 22039268»PubMed
39. SCOT-HEART Investigators., Newby DE, Adamson PD ym. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med 2018;379:924-933 «PMID: 30145934»PubMed
40. Sharma A, Coles A, Sekaran NK ym. Stress Testing Versus CT Angiography in Patients With Diabetes and Suspected Coronary Artery Disease. J Am Coll Cardiol 2019;73:893-902 «PMID: 30819356»PubMed
41. Tam DY, Dharma C, Rocha R ym. Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Diabetes and Multivessel Coronary Disease. J Am Coll Cardiol 2020;76:1153-1164 «PMID: 32883408»PubMed
42. Ungprasert P, Charoenpong P, Ratanasrimetha P ym. Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol 2014;33:1099-104 «PMID: 24859783»PubMed
43. van Halewijn G, Deckers J, Tay HY ym. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. Int J Cardiol 2017;232:294-303 «PMID: 28094128»PubMed
44. Verma S, Farkouh ME, Yanagawa B ym. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2013;1:317-28 «PMID: 24622417»PubMed
45. Wiviott SD, Raz I, Bonaca MP ym. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380:347-357 «PMID: 30415602»PubMed
46. Yiu KH, Mok MY, Wang S ym. Prognostic role of coronary calcification in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol 2012;30:345-50 «PMID: 22409930»PubMed
47. Zinman B, Wanner C, Lachin JM ym. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117-28 «PMID: 26378978»PubMed